Over the past five years, the Brazilian Patent and Trademark Office (BPTO) has adopted various measures to reduce the backlog in patent examinations and implemented several improvements in its examination guidelines to enable high-quality technical examinations to be performed. In addition, the covid-19 pandemic has led to other sensitive discussions regarding the Brazilian patent system and its impact on public health issues. This article provides an overview of six topics that directly affect life sciences patents in Brazil.
Por se tratar de um mercado extremamente inovador e em constante evolução, a Propriedade Intelectual é um dos ramos do direito que a Indústria dos Games não pode dispensar.
On September 02, Bill no. 12/21 was sanctioned in Brazil, aiming to amend the provisions of compulsory licenses set forth by the Brazilian IP Law in cases of national or international emergency, and in case of public interest or recognition of public calamity nationwide, as well.
Sancionada na semana passada, a lei que elimina a exigência de autorização prévia da Agência Nacional de Vigilância Sanitária (Anvisa) para pedidos de patente de produtos farmacêuticos vai acelerar a tramitação de 1.134 processos.
Law no. 14,195 was sanctioned last Thursday (August 27) and it eliminates the requirement of prior consent from the Brazilian Health Surveillance Agency (ANVISA) for patent applications related to pharmaceutical products and processes before the technical examination performed by the Brazilian PTO, which was established in Article 229-C of the Brazilian Industrial Property Law.
O INPI publicará um ato normativo para autorizar o registro, evitando litígios judiciais.
Recently the INPI - National Institute of Industrial Property shared a Public Consultation on the examination of applications for registration of Position Marks (Public Consultation 01/2021), enabling the expression of interested parties in the subject.
Gabriela Salerno, Partner at Montaury Pimenta, Machado & Vieira de Mello, provides an overview of six topics introduced with the latest Guidelines for Life Sciences patents in Brazil.
Although the Brazilian General Data Protection Law (“LGDP”) came into force on September 18, 2020, only after August 1st , 2021 the National Data Protection Authority (“ANPD”) is authorized to impose administrative fines on those caught violating its legal provisions.
Embora a Lei Geral de Proteção de Dados – LGDP – tenha entrado em vigor em 18 de setembro de 2020, somente a partir de 1º de agosto de 2021 a Autoridade Nacional de Proteção de Dados – ANPD – está autorizada a aplicar penas administrativas àqueles que forem flagrados violando suas disposições legais.